专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明申请

WO02064838A3 AMPLIFIED CANCER GENE WIP1 审中-公开
标题翻译：放大癌基因WIP1
公开(公告)号：WO02064838A3
公开(公告)日：2003-10-16
申请号：PCT/US0203991
申请日：2002-02-12
申请人： TULARIK INC , LI JING , POWERS SCOTT
发明人： LI JING , POWERS SCOTT
IPC分类号： A61K48/00 , C12Q1/68 , G06F19/00
CPC分类号： C12Q1/6886 , C12Q2600/158 , Y02A90/26
摘要： There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the WIP1 gene, which are amplified breast, and/or lung, and/or colon, and/or ovarian, and/or prostate cancer genes. The WIP1 gene, its expressed protein products and antibodies are used diagnostically or as targets for cancer therapy; they are also used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.
摘要翻译：公开了利用扩增乳房和/或肺，和/或结肠和/或卵巢的WIP1基因的哺乳动物例如人的肿瘤和癌症的诊断，预防和治疗的方法和组合物。，和/或前列腺癌基因。 WIP1基因，其表达的蛋白质产物和抗体用于诊断或作为癌症治疗的靶标; 它们也用于鉴定可用于癌症诊断，预防和治疗的化合物和试剂。

32. 发明申请

WO2003079982A2 GENE AMPLIFICATION IN CANCER 审中-公开
标题翻译：癌基因扩增
公开(公告)号：WO2003079982A2
公开(公告)日：2003-10-02
申请号：PCT/US2003/008305
申请日：2003-03-18
申请人： TULARIK INC. , LI, Jing , POWERS, Scott , YANG, Jianxin
发明人： LI, Jing , POWERS, Scott , YANG, Jianxin
IPC分类号： A61K
CPC分类号： C12Q1/6886 , C12Q2600/106 , C12Q2600/136 , C12Q2600/156 , Y10T436/143333
摘要： There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals, for example, humans, utilizing the CTSZ and CD24 genes, which are amplified colon cancer and/or ovarian cancer and/or breast cancer genes. The CTSZ and CD24 genes, their expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or vaccine; they also are used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy.
摘要翻译：公开了利用扩增的结肠癌和/或卵巢癌和/或乳腺癌基因的CTSZ和CD24基因来诊断，预防和治疗哺乳动物（例如人）中的肿瘤和癌症的方法和组合物。 CTSZ和CD24基因，其表达的蛋白质产物和抗体用于诊断或作为癌症治疗或疫苗的靶标; 它们也用于鉴定可用于癌症诊断，预防和治疗的化合物和试剂。

33. 发明申请

WO0220463A3 FXR MODULATORS 审中-公开
标题翻译： FXR调制器
公开(公告)号：WO0220463A3
公开(公告)日：2003-08-21
申请号：PCT/US0127239
申请日：2001-08-31
申请人： TULARIK INC , HOUZE JONATHAN , MCKENDRY SHARON , GERGELY JOSHUA P , XIA YI , SHAN BEI , KAYSER FRANK
发明人： HOUZE JONATHAN , MCKENDRY SHARON , GERGELY JOSHUA P , XIA YI , SHAN BEI , KAYSER FRANK
IPC分类号： A61P35/00 , C07C233/75 , C07C237/22 , C07C311/19 , C07C311/29 , C07D209/48 , C07D241/44 , C07D279/02 , A61K31/16 , C07C311/17 , C07K14/705
CPC分类号： C07D209/48 , C07C233/75 , C07C237/22 , C07C311/19 , C07C311/29 , C07C2601/14 , C07D241/44 , C07D279/02
摘要： The present invention provides compounds, pharmaceutical compositions and methods that are useful in modulating the farnesoid X receptor (FXR). As FXR is involved in negatively controlling the expression level of cholesterol 7 alpha -hydroxylase (cyp7a), the rate-limiting enzyme involved in the oxidative metabolism of cholesterol into bile acids, the compounds described herein find utility in treating diseases associated with abnormally high or low cholesterol levels. In certain aspects, the FXR modulators (e.g., antagonists) described herein block the negative feed-back downregulation of cyp7a expression produced by certain cholic acids, the endogenous ligands for FXR. Moreover, as FXR forms heterodimers with the retinoid X receptor (RXR) in some cell types, modulation of the level of FXR activity in cells has a wide range of effects on a variety of biological processes which are mediated by RXR or other RXR-interacting proteins such as PPAR gamma and PPAR alpha . Thus, compounds described herein are useful in treating other biological activities such as obesity, diabetes, lipid associated disorders, cancer, inflammatory disorders, disorders involving a disrupted or dysfunctional epidermal barrier, and various other metabolic disorders.
摘要翻译：本发明提供了可用于调节法呢酯X受体（FXR）的化合物，药物组合物和方法。由于FXR涉及负调控胆固醇7α-羟化酶（cyp7a）的表达水平，涉及胆固醇胆固醇氧化代谢的限速酶，本文所述的化合物可用于治疗与异常高相关的疾病或低胆固醇水平在某些方面，本文所述的FXR调节剂（例如拮抗剂）阻断某些胆酸（FXR的内源性配体）产生的cyp7a表达的负反馈下调。此外，由于FXR在一些细胞类型中与类视黄醇X受体（RXR）形成异源二聚体，因此细胞中FXR活性水平的调节对由RXR或其他RXR相互作用介导的各种生物过程具有广泛的影响蛋白质如PPARγ和PPARα。因此，本文所述的化合物可用于治疗其它生物活性，例如肥胖症，糖尿病，脂质相关疾病，癌症，炎性疾病，涉及破坏性或功能失调的表皮屏障的疾病以及各种其它代谢紊乱。

34. 发明申请

WO0177067A3 SOLID PHASE SYNTHESIS OF LXR LIGANDS 审中-公开
标题翻译： LXR配体的固相合成
公开(公告)号：WO0177067A3
公开(公告)日：2003-08-14
申请号：PCT/US0111242
申请日：2001-04-05
申请人： TULARIK INC , SUMITOMO PHARMACEUTICALS , MEDINA JULIO , IMAZAKI NAONORI
发明人： MEDINA JULIO , IMAZAKI NAONORI
IPC分类号： A61P9/10 , C07B61/00 , C07C231/02 , A61K31/167
CPC分类号： C07C231/02 , C07B2200/11 , C40B40/00
摘要： The invention provides solid support synthetic methods for producing combinatorial libraries of modulators of LXRs. The combinatorial libraries thus produced are useful both as diagnostic indicators of LXR alpha function and as pharmacologically active agents. The combinatorial libraries find particular use in the treatment of disease states associated with cholesterol metabolism, particularly atherosclerosis and hypercholesterolemia.
摘要翻译：本发明提供了用于生成LXR调节剂组合文库的固体支持合成方法。因此产生的组合文库既可用作LXRα功能的诊断指标，也可用作药理活性剂。组合文库特别用于治疗与胆固醇代谢相关的疾病状态，特别是动脉粥样硬化和高胆固醇血症。

35. 发明申请

WO2003063796A3 HETEROCYCLIC ARYLSULFONAMIDOBENZYLIC COMPOUNDS 审中-公开
公开(公告)号：WO2003063796A3
公开(公告)日：2003-08-07
申请号：PCT/US2003/003148
申请日：2003-01-29
申请人： TULARIK INC. , JIAO, Xian, Yun , KAYSER, Frank , KOPECKY, David, J. , PIPER, Derek, E. , SHIAU, Andrew, K. , MCKENDRY, Sharon
发明人： JIAO, Xian, Yun , KAYSER, Frank , KOPECKY, David, J. , PIPER, Derek, E. , SHIAU, Andrew, K. , MCKENDRY, Sharon
IPC分类号： C07D207/335
摘要： Heterocyclic arylsulfonamidobenzylic compounds are provided which are useful in treating lipid disorders, metabolic disorders and cell-proliferative diseases.

36. 发明申请

WO2003063796A2 HETEROCYCLIC ARYLSULFONAMIDOBENZYLIC COMPOUNDS 审中-公开
标题翻译：杂环芳基磺酰氨基苯甲酸化合物
公开(公告)号：WO2003063796A2
公开(公告)日：2003-08-07
申请号：PCT/US2003/003148
申请日：2003-01-29
申请人： TULARIK INC. , JIAO, Xian, Yun , KAYSER, Frank , KOPECKY, David, J. , PIPER, Derek, E. , SHIAU, Andrew, K. , MCKENDRY, Sharon
发明人： JIAO, Xian, Yun , KAYSER, Frank , KOPECKY, David, J. , PIPER, Derek, E. , SHIAU, Andrew, K. , MCKENDRY, Sharon
IPC分类号： A61K
CPC分类号： C07D207/333 , C07D207/335
摘要： Heterocyclic arylsulfonamidobenzylic compounds are provided which are useful in treating lipid disorders, metabolic disorders and cell-proliferative diseases.
摘要翻译：提供了可用于治疗脂质失调，代谢失调和细胞增殖性疾病的杂环芳基磺酰氨基苯甲酸化合物。

37. 发明申请

WO02062958A3 PRC17: AN AMPLIFIED CANCER GENE 审中-公开
标题翻译： PRC17：放大癌基因
公开(公告)号：WO02062958A3
公开(公告)日：2003-04-10
申请号：PCT/US0203457
申请日：2002-02-08
申请人： TULARIK INC , LI JING , POWERS SCOTT , XIANG PHIL , PENG YUE
发明人： LI JING , POWERS SCOTT , XIANG PHIL , PENG YUE
IPC分类号： A61K38/00 , C07K14/82 , C12Q1/68 , G01N33/574 , C07H21/02 , C07K1/00
CPC分类号： C07K14/82 , A61K38/00 , C12Q1/6886 , C12Q2600/156 , C12Q2600/158 , G01N33/57415 , G01N33/57423 , G01N33/57434 , G01N33/57449 , G01N2800/52
摘要： The present invention provides nucleic acid and protein sequences for a novel protein, PRC17, and methods, reagents, and kits for diagnosing and treating cancer in a mammal, e.g., a human. This invention is based upon the discovery that the novel PRC17 is overexpressed and/or amplified in cancer. Methods to detect cancer or a propensity to develop cancer, to monitor the efficacy of a cancer treatment, and to treat cancer, by inhibiting the expression and/or activity of PRC17 in a cancer cell are included.
摘要翻译：本发明提供新型蛋白质PRC17的核酸和蛋白质序列，以及用于诊断和治疗哺乳动物（例如人）中的癌症的方法，试剂和试剂盒。本发明是基于这样的发现：新型PRC17在癌症中过表达和/或扩增。包括通过抑制癌细胞中PRC17的表达和/或活性来检测癌症或倾向于发展癌症，监测癌症治疗的功效和治疗癌症的方法。

38. 发明申请

WO2003024395A3 LINKED BIARYL COMPOUNDS 审中-公开
公开(公告)号：WO2003024395A3
公开(公告)日：2003-03-27
申请号：PCT/US2002/029232
申请日：2002-09-13
申请人： TULARIK INC. , JAPAN TOBACCO, INC. , ABE, Hiroyuki , HOUZE, Jonathan , KAWASAKI, Hisashi , KAYSER, Frank , SHARMA, Rajiv , SPERRY, Samuel
发明人： ABE, Hiroyuki , HOUZE, Jonathan , KAWASAKI, Hisashi , KAYSER, Frank , SHARMA, Rajiv , SPERRY, Samuel
IPC分类号： A61K31/415
摘要： Compounds, compositions and methods that are useful for the treatment of metabolic disorders, inflammatory diseases and cancer are provided herein. In particular, the invention provides compounds which modulate the expression and/or function of proteins involved in lipid metabolism, inflammation and cell proliferation. The subject compounds are linked biaryl compounds.

39. 发明申请

WO2003018770A2 AMPLIFIED ONCOGENES AND THEIR INVOLVEMENT IN CANCER 审中-公开
标题翻译：放大的癌症及其在癌症中的参与
公开(公告)号：WO2003018770A2
公开(公告)日：2003-03-06
申请号：PCT/US2002/027188
申请日：2002-08-27
申请人： TULARIK INC. , MU, David , POWERS, Scott
发明人： MU, David , POWERS, Scott
IPC分类号： C12N
CPC分类号： C12Q1/6886 , C07K14/575 , C07K14/72 , C12N15/1136 , C12N15/1138 , C12N2310/14 , C12Q2600/156 , Y02A90/26
摘要： There are disclosed methods and compositions for the diagnosis, prevention, and treatment of tumors and cancers in mammals such as humans, utilizing the Galanin, Galanin Receptor 2 (GALR2) and Galanin Receptor 3 (GALR3) genes, which are amplified in breast and/or lung and/or brain and/or colon and/or prostate and/or ovarian cancer genes. The Galanin, GALR2 and GALR3 genes and their expressed protein products and antibodies are used diagnostically or as targets for cancer therapy or vaccine; they are also used to identify compounds and reagents useful in cancer diagnosis, prevention, and therapy. There is also disclosed a GALR2-GALR3 heterocomplex formation during tumorigenesis.
摘要翻译：公开了利用Galanin，Galanin受体2（GALR2）和Galanin受体3（GALR3））基因在哺乳动物（例如人）中诊断，预防和治疗肿瘤和癌症的方法和组合物，其在乳腺和/ 或肺和/或脑和/或结肠和/或前列腺和/或卵巢癌基因。 Galanin，GALR2和GALR3基因及其表达的蛋白质产物和抗体用于诊断或作为癌症治疗或疫苗的靶标; 它们也用于鉴定可用于癌症诊断，预防和治疗的化合物和试剂。还在肿瘤发生过程中披露了GALR2-GALR3异复合物形成。

40. 发明申请

WO02064096A3 METHODS OF USING PYRIMIDINE-BASED ANTIVIRAL AGENTS 审中-公开
标题翻译：使用基于吡啶基的抗病毒剂的方法
公开(公告)号：WO02064096A3
公开(公告)日：2003-03-06
申请号：PCT/US0204920
申请日：2002-02-14
申请人： TULARIK INC , JAEN JUAN C
发明人： JAEN JUAN C
IPC分类号： A61K31/505 , A61K31/506 , A61K31/513 , A61K31/55 , A61K45/06 , A61P37/08 , A61K31/495 , A61K31/535
CPC分类号： A61K45/06 , A61K31/505 , A61K31/506 , A61K31/513 , A61K31/55 , A61K2300/00
摘要： The invention provides novel methods of using substituted pyrimidine compounds and compositions for the treatment or prevention of diseases associated with CMV infection. In particular, the present invention provides methods for the treatment or prevention of cardiovascular diseases and organ transplant rejection.
摘要翻译：本发明提供了使用取代的嘧啶化合物和组合物治疗或预防与CMV感染有关的疾病的新方法。特别地，本发明提供了用于治疗或预防心血管疾病和器官移植排斥的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式